Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Other Non-Current Assets (2016 - 2025)

OptimizeRx (OPRX) has disclosed Other Non-Current Assets for 15 consecutive years, with $112.1 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 4.23% to $112.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $112.1 million through Dec 2025, down 4.23% year-over-year, with the annual reading at $112.1 million for FY2025, 4.23% down from the prior year.
  • Other Non-Current Assets hit $112.1 million in Q4 2025 for OptimizeRx, down from $113.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $117.0 million in Q4 2024 to a low of $362000.0 in Q3 2024.
  • Historically, Other Non-Current Assets has averaged $51.3 million across 5 years, with a median of $36.0 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 99.01% in 2024 and later surged 31359.12% in 2025.
  • Year by year, Other Non-Current Assets stood at $25.7 million in 2021, then skyrocketed by 39.68% to $35.9 million in 2022, then crashed by 98.42% to $568000.0 in 2023, then surged by 20506.87% to $117.0 million in 2024, then dropped by 4.23% to $112.1 million in 2025.
  • Business Quant data shows Other Non-Current Assets for OPRX at $112.1 million in Q4 2025, $113.9 million in Q3 2025, and $115.1 million in Q2 2025.